Research programme: humabody VH antibody fragment-based CAR-T cells - Crescendo Biologics/ University of North Carolina
Alternative Names: MSLN VH CAR-T cell therapy-Crescendo Biologics/ University of North Carolina; PSMA VH CAR-T cell therapy-Crescendo Biologics/ University of North CarolinaLatest Information Update: 03 Sep 2024
Price :
$50 *
At a glance
- Originator Crescendo Biologics; University of North Carolina
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunoglobulin fragments; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 03 Sep 2024 No development reported - Preclinical for Solid tumours in United Kingdom (Parenteral) (Crescendo Biologics pipeline, September 2024)
- 03 Sep 2024 No development reported - Preclinical for Solid tumours in USA (Parenteral) (Crescendo Biologics pipeline, September 2024)
- 16 Apr 2021 Preclinical trials in Solid tumours in United Kingdom (Parenteral)